top of page

TESTING SERVICES

COVID-19

OmniHealth Diagnostics is helping to combat the Covid-19 pandemic by providing SARS-CoV-2, RNA (HT) and SARS-CoV-2, Total Antibodies (IgM, IgG) results within 24-48 hours of lab receiving your sample. All insurances are accepted. Cash prices for SARS-CoV-2, RNA (HT) is $325 and SARS-CoV-2, Total Antibodies (IgM, IgG) is $140.

Infectious Disease
Covid-19

INFECTIOUS DISEASE

(PCR) Assays are the most commonly used molecular technique to detect and study microbes. As compared to other methods, sequencing and analysis are definitive, reliable, accurate, and fast. OmniHealth Diagnostics uses the most advanced leading edge technology by Roche Diagnostics to perform infectious Diseases testing.

Hereditary Cancer

HEREDITARY CANCER

GENETIC TESTING

Though we have not identified genetic causes for all types of cancer, there is an inherent lifetime risk of developing cancer that is exhibited in every 1 of 3 individuals in the USA, per the National Cancer Institute. The majority of cancers are random in nature and are affected by a host of factors including gender, age, race, diet, disease, and environmental influences. However, we do know of several cancers that are affected by mutations that can be passed down from parent to child and increase a person's risk of developing the disease. These changes are known as hereditary cancers and account for approximately 5-10% of all cancer cases. Individuals who are at a higher risk have a history of affected family members with the same type or similar cancers and those who have previously been diagnosed with cancer. Identifying at risk individuals for a hereditary predisposition to cancer can aid through early intervention using precision screening and allowing for the opportunity to increase surveillance.

Hereditary Cardiac

HEREDITARY CARDIAC

GENETIC TESTING

As of 2019, the Center for Disease Control and Prevention lists cancer and heart disease as the two leading causes of death for adults aged 45-64, accounting for 50% of all deaths within this age range. Cardiovascular diseases often involve connective tissues which maintain and segment the human body. There are often overlapping features and variable stages which can complicate a true clinical diagnosis. Our cardiovascular cancer panels can be ordered individually or comprehensively that include testing for RASopathies, cardiomyopathy, arrhythmia, inherited cholesterol disorders and connective tissue disorders. We also offer a specialty panel which targets familial hypercholesterolemia (high cholesterol). This test is targeted to those who exhibit higher LDL cholesterol levels at an early age or who have sustained increased LDL cholesterol levels. Hypercholesterolemia can lead to an increased risk for cardiovascular disease and is the most common inherited cardiovascular disease with a prevalence of 1 in 200 individuals, and accounts for 2%-3% of myocardial infractions in young individuals. Testing for those who are at-risk promotes correct identification of the various overlapping syndromes and allows for proper management and awareness for your risk of developing disease.

Pharmacogenomics

PHARMACOGENOMICS

Pharmacogenomics (PGx) is the study of how genetic differences within your genes influence the bodies response to certain medications. A single person has an estimated 30,000 genes that carry information that encodes your unique traits, such as height and eye color. At the root of DNA, all humans are 99.9% identical in genetic makeup, but differences in the remaining 0.1% hold important clues about how safe and effective a particular drug could be for you. Many drugs currently on the market are standardized with a “one size fits all” mentality, but these drugs do not work the same way for everyone. This is the reason the same medication at the same dose will vary from person to person, and why some people experience adverse side effects to a certain medication, while others have none. OmniHealth understands the benefits of precision and preventative medicine, which is why we pride ourselves as one of very few laboratories who are on the forefront to personalized medicine. Our laboratory specializes in genomics and has developed a proprietary PGx panel that targets those genes within the 0.1% to help determine the types of medications and dosage that is right for you.

TOXICOLOGY

OmniHealth Diagnostics utilizes liquid chromatography coupled with mass spectrometry (LC-MS) as an analytical technique for the determination of analyte concentrations in a sample. The technique is notable for the specificity of the results is the preferred industry method of testing. Medication monitoring and drug detection services from OmniHealth Diagnostics ensure that clinicians can choose drug classes individually, based on medical necessity, rather than being obligated to use a one-size-fits-all, pre-set panel of tests.

OmniHealth Diagnostics test menu continues to expand, reflecting the most current prescribed medications and an ever-evolving list of illicit substances, emerging medications, and drugs. We have advanced our LC-MS technology to provide drug specific identification and quantification for more than 115 drugs and metabolites.

QUALITATIVE URINE DRUG SCREEN

URINE VALIDITY

QUANTITATIVE CONFIRMATION (LCMS)

Image - PID.jpg

PRIMARY IMMUNODEFICIENCY

Primary Immunodeficiency analyzes genes that are associated with inherited disorders of the immune system.

Primary Immunodeficiency
Toxicology
bottom of page